CAS 2260886-64-2

N-(trans-4-(3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)cyclohexyl)propionamide

CAS: 2260886-64-2

Fórmula: C₃₃H₄₁ClN₈O₂

Pureza: 98%

Peso molecular: 617.184

Ref: IN-DA01KL3B

N-(Trans-4-(3-(2-Chlorophenyl)-7-((3-Methyl-4-(4-Methylpiperazin-1-Yl)Phenyl)Amino)-2-Oxo-3,4-Dihydropyrimido[4,5-D]Pyrimidin-1(2H)-Yl)Cyclohexyl)Propionamide

CAS: 2260886-64-2

N-(Trans-4-(3-(2-Chlorophenyl)-7-((3-Methyl-4-(4-Methylpiperazin-1-Yl)Phenyl)Amino)-2-Oxo-3,4-Dihydropyrimido[4,5-D]Pyrimidin-1(2H)-Yl)Cyclohexyl)Propionamide

Pureza: 99%

Peso molecular: 617.18g/mol

Ref: 54-OR1023782

JND3229

CAS: 2260886-64-2

JND3229 is a synthetic, non-small-cell EGFR inhibitor that targets the kinase domain of EGFR. It has been shown to inhibit the proliferation of mutant EGFR cell lines in vitro and in vivo, as well as tumor growth in xenograft models. JND3229 has also been shown to suppress tumor growth and prolong survival in a mouse model of metastatic cancer. The mechanism of action for this drug is inhibition of the tyrosine kinase activity that is essential for the activation of downstream signaling pathways.

Fórmula: C₃₃H₄₁ClN₈O₂

Pureza: Min. 95%

Peso molecular: 617.2 g/mol

Ref: 3D-KQD88664

JND3229

CAS: 2260886-64-2

JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.

Fórmula: C₃₃H₄₁ClN₈O₂

Pureza: 98.75%

Cor e Forma: Solid

Peso molecular: 617.18

Ref: TM-T15615